The immunotherapy SurVaxM is being utilized in a pilot study in children and adolescents with several brain cancer types through a multicenter trial sponsored by the Pediatric Brain Tumor Consortium (PBTC).
New research led by Kara Kelly, MD, of Roswell Park Comprehensive Cancer Center and presented today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago shows that a combination of brentuximab vedotin (Bv) and standard chemotherapy is safe and more effective than standard chemotherapy in pediatric patients up to age 21 years with newly diagnosed high-risk Hodgkin lymphoma. The findings from a phase 3 National Cancer Institute-supported multicenter Children’s Oncology Group clinical trial (NCT 02166463) were presented by first author Sharon Castellino, MD, of Emory University and Children’s Healthcare of Atlanta in an oral abstract session on Friday, June 3.
Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for patients with advanced tumors.
Evolution Research Group, LLC (ERG), a privately held, independent pharmaceutical services provider focused on neuroscience announced the acquisition of Ohio Clinical Trials (OCT), a 64-bed phase 1 unit in Columbus, OH, that specializes in the execution of human abuse potential (HAP) studies, as well as other highly complex early phase trials including pain modeling, qEEG/EEG, respiratory depression, and alcohol interaction, among others.
Experts from Cedars-Sinai Cancer are available to comment on the American Association for Cancer Research (AACR) Cancer Disparities Progress Report 2022, which will be released Wednesday, June 8, in a virtual congressional briefing. The report highlights the need to increase diversity in clinical trials and the cancer workforce, and it provides policy recommendations for addressing cancer disparities—all areas Cedars-Sinai Cancer is working to address.
On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML), in a talk at the American Society of Clinical Oncology (ASCO) annual meeting 2022.
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.
A combination of chemotherapy with an immunotherapy meant to unleash the anticancer capacity of the immune system was effective against one of the hardest targets in cancer care, pancreatic cancer, in a national, randomized clinical trial led by researchers at the Perelman School of Medicine at the University of Pennsylvania, and sponsored by the Parker Institute for Cancer Immunotherapy.
Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug combination could extend the lives of those diagnosed with advanced non-small cell lung cancer, one of the most common forms of lung cancer. The research was presented today during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, with simultaneous publication in the peer-reviewed Journal of Clinical Oncology.
Researchers from Roswell Park Comprehensive Cancer Center will present the latest results of clinical trials and insights on cancer treatment and issues affecting patients with cancer, including the financial burdens induced by cancer treatment, at the annual meeting of the American Society of Clinical Oncology (ASCO), which will take place both online and in-person in Chicago, Illinois, from June 3 to 7.
A University of Miami Miller School of Medicine researcher is hoping an innovative multicenter clinical trial will lead to new therapies for neurofibromatosis type 2 (NF2), a devastating disease causing multiple types of tumors involving the brain, spine, and peripheral nerves.
Cells produce proteins like little factories. But if they make too much at the wrong times it can lead to diseases like cancer, so they control production with a process called RNA interference (RNAi).
Researchers at Washington University School of Medicine in St. Louis have developed a way to attack synovial sarcoma — a rare tumor of soft tissues, such as ligaments and muscles — using an investigational drug that triggers cell death.
Researchers at Saint Louis University School of Medicine are enrolling volunteers in an investigational drug trial for hypogonadal men with chronic kidney disease.
The 2022 Annual Report from Cedars-Sinai Cancer, which is available now, shines a spotlight on ways this expert team, ranked among the top 10 in the nation for cancer care by U.S. News & World Report, has treated more than 60 types of cancer while honoring and expanding a long-standing commitment to health equity.
Indiana University's Amy Knopf can speak about the impacts of a recent National Academies of Sciences, Engineering, and Medicine report, "Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups."
Susan G. Komen awarded a research grant to apply a new, first-of-its-kind tool that seeks to more accurately diagnose inflammatory breast cancer (IBC).
V-Wave Ltd, manufacturer of the V-Wave Ventura investigational interatrial shunt device to help patients with advanced heart failure (HF), announced 12-month echocardiographic results from the open label Roll-in arm of the RELIEVE-HF pivotal clinical trial, comprising 97 NYHA Class III or ambulatory Class IV HF patients who were already on maximally tolerated guideline directed medical therapy.
Curtin University researchers will examine if the long-term use of a popular blood pressure medication increased the risk of breast cancer in almost 200,000 women as part of a new project supported by the Federal Government.
Patients with severe COVID-19 who were given imatinib had lower mortality rates at 90-day follow-up, according to research published at the ATS 2022 international conference.
People who are highly responsive to food lost more weight and kept it off using a new weight loss program that targets internal hunger cues and the ability to resist food, reports University of California San Diego Herbert Wertheim School of Public Health and Human Longevity Science.
SEATTLE (May 18, 2022) – Building on momentum from the highly successful COVID-19 vaccine clinical trials, the HIV Vaccine Trials Network (HVTN) is launching a new HIV awareness campaign and unveiling a first-of-its-kind national registry that will provide updated HIV information and make it easier to learn about and participate in HIV clinical trials at HelpEndHIV.org.
The Pulmonary Fibrosis Foundation (PFF) has developed new materials and tools for people living with pulmonary fibrosis (PF) to learn about and enroll in
clinical research studies.
University Hospitals’ Jonathan Shoag, MD, and a team of researchers from Case Western Reserve University and the Case Comprehensive Cancer Center, Weill Cornell Medical Center, the Fred Hutchinson Cancer Research Center, and others, set out to assess the tradeoffs of PSA screening using long-term epidemiologic data. “No matter the assumptions,” Shoag said, “the data showed lower numbers than prior estimates, many in the low single digits, for the number needed to treat to prevent a prostate-cancer death. This result was observed in all men, and especially for Black men.” The researchers presented their findings in a late-breaking abstract at the American Urological Association’s annual meeting this month and the study was published May 15 in The New England Journal of Medicine Evidence.
In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma.
Background: Combination therapies delivered remotely via the internet or mobile devices are increasingly being used to improve and promote the self-management of chronic conditions. However, little is known regarding the long-term ef...
A novel technology designed to precisely image aggressive brain cancers and guide treatment is being developed by the University of South Australia and Australian cancer diagnostic company, Ferronova, potentially helping thousands of people who are diagnosed with the deadly condition each year.
A suite of complimentary tests can quantify changes in dogs suspected of suffering from cognitive decline. The approach could benefit dogs and serve as a model for evaluating cognitive decline progression in – and treatments for – humans with Alzheimer’s disease.
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events from immunotherapy treatment by targeting the cytokine interleukin-6 (IL-6).
The University of Maryland School of Medicine (UMSOM) is the joint recipient of $4.75 million in funding from the National Science Foundation to establish a new Center for Medical Innovations in Extended Reality.
Background: Although well recognized for its scientific value, data sharing from clinical trials remains limited. Steps toward harmonization and standardization are increasing in various pockets of the global scientific community. Th...
When patients in the UK started showing adverse side effects during a cancer immunotherapy trial, researchers at La Jolla Institute for Immunology (LJI) Center for Cancer Immunotherapy and University of Liverpool went back through the data and worked with patient samples to see what went wrong.
A stroke and subsequent brain injury qualified 65-year-old Linda Carmichael for a national, randomized clinical trial led locally by Sunil A. Sheth, MD, with McGovern Medical School at UTHealth Houston, investigating the safety and efficacy of endovascular thrombectomy plus medical management compared to medical management alone in certain LVO stroke patients.
A team of researchers from the National University of Singapore is pioneering a novel magnetic therapy as an effective companion therapy to chemotherapy for treatment of breast cancer. This therapy is localised, non-invasive and painless, and could improve the overall treatment outcome.
Ochsner Baton Rouge electrophysiologist Dr. Freddy Abi-Samra has successfully completed the region’s first heart pacemaker procedure in a clinical trial involving a new, breakthrough technology that could make pacemaker surgery available to patients who may not benefit from traditional technology.
The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to The TOGETHER Trial: An Adaptive Platform International Trial.
In hospitalized patients with COVID-19, the SGLT2 inhibitor dapagliflozin was well tolerated regardless of kidney function, but did not significantly lower patients’ risk of organ failure, kidney problems, or death compared with placebo.
Based upon a clinical trial of pregnant women at more than 70 sites, including Ochsner Health, doctors are recommending that even mild forms of high blood pressure be treated with medication.
CAR-T therapy, a form of immunotherapy that revs up T-cells to recognize and destroy cancer cells, has revolutionized the treatment of blood cancers, including certain leukemias, lymphomas, and most recently, multiple myeloma. However, Black and Hispanic people were largely absent from the major clinical trials that led to the U.S. Food and Drug Administration approval of CAR-T cell therapies.
Cardiologists and cardiothoracic surgeons from the Smidt Heart Institute at Cedars-Sinai are available to discuss the latest advances in research, clinical care, transcatheter procedures and cardiothoracic surgery throughout the International Society for Heart and Lung Transplantation (ISHLT) Scientific Sessions 2022 and Heart Rhythm 2022.
With the support of a $1.7 million grant from the National Institutes of Health, researchers at the School of Medicine will lead the Long-term Effectiveness of the Anti-Obesity medication Phentermine (LEAP) trial, a placebo-controlled, randomized-controlled trial that will enroll 1,000 adults at five sites across the U.S.
In a research letter to the journal JAMA Oncology, clinical researchers at Sylvester Comprehensive Cancer Center in the University of Miami Miller School of Medicine showed that immunotherapy can be an option for at least one subgroup of pancreatic cancer patients. The study found that patients with inherited BRCA and other similar mutations can achieve complete responses — in some cases going from near death to durable recoveries.
Bladder cancer affects nearly 84,000 people in the United States each year, making it the sixth most common cancer. Most people survive it, but unfortunately, many lose their bladders. Neda Hashemi, MD, and her team at The University of New Mexico Comprehensive Cancer Center are now offering several clinical trials, including one that will give people with bladder cancer a chance to fight their disease and keep their bladders.